Xeris Biopharma, Inc.
180 N LaSalle St
Suite 1600
Chicago
IL
60601
United States
Tel: 512-534-8340
Website: http://xerispharma.com/
Email: info@xerispharma.com
173 articles about Xeris Biopharma, Inc.
-
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Feb. 28, 2020
2/28/2020
Xeris Pharmaceuticals, Inc. announced that on February 26, 2020, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 6,000 shares of its common stock to 1 new employee under Xeris’ Inducement Equity Plan.
-
Xeris Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on March 11, 2020
2/27/2020
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, announced that the Company will release its fourth quarter and full year 2019 financial results before the opening of the U.S. financial markets on Wednesday, March 11, 2020.
-
Xeris Pharmaceuticals Announces Exercise of Underwriters’ Option to Purchase Additional Shares - Feb. 20, 2020
2/20/2020
Xeris Pharmaceuticals, Inc. announced that, in connection with its previously announced underwritten public offering of shares of common stock, the underwriters partially exercised their option to purchase an additional 1,299,769 shares of common stock from the Company out of the 1,350,000 total shares underlying the option.
-
Xeris Pharmaceuticals to Participate at SVB Leerink Global Healthcare Conference
2/18/2020
Feb. 18, 2020 14:00 UTC CHICAGO--( BUSINESS WIRE )-- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, will participate in a fireside chat at the 9th Annual SVB Leerink Global Healthcare Conference. Date: Tuesday, February 2
-
Xeris Pharmaceuticals Announces Pricing of Public Offering of Shares of Common Stock
2/12/2020
Xeris Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 9,000,000 shares of its common stock at a public offering price of $4.15 per share, before underwriting discounts and commissions and other offering expenses, for gross proceeds of approximately $37.4 million.
-
Xeris Pharmaceuticals Announces Proposed Public Offering of 6,000,000 Shares of Common Stock
2/10/2020
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock.
-
Xeris Pharmaceuticals Announces Positive Results from the In-Clinic Stage of a Phase 2 Study of Its Developmental Ready-To-Use (RTU) Glucagon in Patients at Risk of Hypoglycemia During and after Aerobic Exercise
1/6/2020
Results show a mini dose (150 µg) of RTU glucagon prevents Exercise-Induced Hypoglycemia (EIH) during prolonged, moderate-to-high intensity aerobic exercise in a clinical research setting
-
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec. 27, 2019
12/27/2019
Xeris Pharmaceuticals, Inc. announced that on December 24, 2019, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 14,500 shares of its common stock to 3 new employees under Xeris’ Inducement Equity Plan.
-
Xeris Pharmaceuticals Announces Positive Topline Results From the In-clinic Stage of the Phase 2 Study of Its Developmental Ready-to-use (RTU) Glucagon in Patients at Risk of Postprandial Hypoglycemia Following Bariatric Surgery
12/10/2019
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced positive topline results from the in-clinic stage of a Phase 2 study of its developmental ready-to-use (RTU) glucagon in patients who experience postprandial hypoglycemic episodes following bariatric surgery.
-
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 27, 2019
11/29/2019
Xeris Pharmaceuticals, Inc. announced that on November 27, 2019, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 8,000 shares of its common stock to 4 new employees under Xeris’ Inducement Equity Plan.
-
Xeris Pharmaceuticals Provides a Business Update During Recent Investor Conference
11/21/2019
MAA submitted to EMA of liquid stable glucagon for severe hypoglycemia
-
Xeris Pharmaceuticals Empowers Their Medical Affairs Team with rMark Bio's Cue
11/20/2019
The role of Medical Affairs is changing, Xeris opts for next gen AI software to stay ahead of the curve.
-
BioSpace takes a look at some of the financing rounds announced over the past few weeks.
-
Xeris Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights
11/7/2019
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, announced financial results for the third quarter and nine months ended September 30, 2019.
-
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11/1/2019
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on October 30, 2019, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 81,000 shares of its common stock to 61 new employees under Xeris’ Inducement Equity Plan.
-
Xeris Pharmaceuticals Begins Dosing Patients in a Phase 2 Clinical Trial Evaluating Its Novel Fixed-Ratio Co-Formulation of Pramlintide-Insulin for Diabetes
9/19/2019
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced it began dosing patients in a Phase 2 clinical study to evaluate its investigational ready-to-use, fixed-ratio co-formulation of pramlintide and insulin in patients with diabetes.
-
The approval marks the first commercial product for Xeris.
-
Xeris Pharmaceuticals Receives U.S. FDA Approval for GVOKE™ (glucagon), the First Ready-to-use Stable Liquid Glucagon for Severe Hypoglycemia
9/10/2019
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, announced today that it has received regulatory approval from the U.S. Food and Drug Administration (FDA) for GVOKE™ (glucagon) injection
-
Xeris Pharmaceuticals Announces Expanded $85 Million Debt Facility With Oxford Finance and Silicon Valley Bank
9/10/2019
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has entered into an amended and restated loan and security agreement with Oxford Finance LLC (Oxford) and Silicon Valley Bank (SVB).
-
In the first two weeks of September there were three scheduled PDUFA dates. One of those dates, for Celgene’s myelofibrosis drug, was approved early. Here’s a look.